

Provider Newsletter



<https://www.summitcommunitycare.com/provider>

August 2019



Table of Contents

Medicaid:

Use the *Practice Profile Update Form* to update your information Page 2

Clinical Criteria updates Page 2

Pharmacy management information Page 2

Upgrade to 23rd edition of MCG Care Guidelines Page 2

Coming soon: electronic attachments Page 3

Medical Policies and Clinical Utilization Management Guidelines update Page 4

Prior authorization requirements Page 5

Reimbursement Policy:

Drug Screen Testing Page 6

All services referenced in this material are funded and provided under an agreement with the Arkansas Department of Human Services.

Use the *Practice Profile Update Form* to update your information



We continually update our provider directories to ensure that your current practice information is available to our members. At least 30 days prior to making any changes to your practice – including updating your address and/or phone number, adding or deleting a physician from your practice, closing your practice to new patients, etc. – please notify us by filling out the *Practice Profile Update Form* available at www.summitcommunitycare.com/provider. Thank you for your help and continued efforts in keeping our records up-to-date.

AR-NL-0035-19

Clinical Criteria updates

On February 22, 2019, and March 14, 2019, the Pharmacy and Therapeutics (P&T) Committee approved *Clinical Criteria* applicable to the medical drug benefit for Summit Community Care. These policies were developed, revised or reviewed to support clinical coding edits.

The *Clinical Criteria* is publicly available on the [provider website](#) and the effective dates will be reflected in the [Clinical Criteria Q1 web posting](#). Visit [Clinical Criteria](#) to search for specific policies.

For questions or additional information, use [this email](#).

AR-NL-0043-19

Pharmacy management information

Need up-to-date pharmacy information?

Log in to our [provider website](#) to access our Formulary, Prior Authorization forms, *Preferred Drug List* and process information.



Have questions about the Formulary or need a paper copy?

Call our Pharmacy department at 1-844-462-0022. Pharmacy technicians are available Monday-Friday from 8:00 a.m.-8:00 p.m. and Saturday from 10:00 a.m.-2:00 p.m. Eastern time.

Our Member Services representatives serve as advocates for our members. To reach Member Services, please call 1-844-405-4295.

AR-NL-0035-19

Upgrade to 23rd edition of MCG Care Guidelines

Effective September 1, 2019, Summit Community Care will upgrade to the 23rd edition of the MCG Care Guidelines. With this annual upgrade, some MCG criteria are being customized.



Please view a summary of the most recent customizations [online](#).

AR-NL-0036-19

Coming soon: electronic attachments

As we prepare for the potential regulatory-proposed standards for electronic attachments, Summit Community Care will be implementing X12 275 electronic attachment transactions (version 5010) for claims.

Standard electronic attachments will bring value to you by eliminating the need for mailing paper records and reducing processing time overall.



Summit Community Care and Availity will pilot electronic data interchange batch electronic attachments with previously selected providers. Both solicited and unsolicited attachments will be included in our pilots.

Attachment types

- **Solicited attachments:** The provider sends a claim, and the payer determines there is not enough information to process the claim. The payer will then send the provider a request for additional information (currently done via letter). The provider can then send the solicited attachment transaction, with the documentation requested, to process the claim.
- **Unsolicited attachment:** When the provider knows that the payer requires additional information to process the claim, the provider will send the X12 837 claim with the Paper Work Included segment tracking number. Next, the provider will send the X12 275 attachment transaction with the additional information and include the tracking number that was sent on the claim for matching.

What you can do

As we prepare for this change, you can help now by having conversations with your clearinghouse and/or electronic health care records vendor to determine their ability to set up the X12 275 attachment transaction capabilities.

In addition, you should be on the lookout for additional information and details about working with Summit Community Care and Availity to send attachments via electronic batch.

AR-NL-0034-19

Medical Policies and Clinical Utilization Management Guidelines update



The *Medical Policies and Clinical Utilization Management (UM) Guidelines* below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed. For markets with carved-out pharmacy services, the applicable listings below are informational only. To view a guideline, visit <https://www.summitcommunitycare.com/provider>.

Notes/updates:

- **MED.00110 – Growth Factors, Silver-based Products and Autologous Tissues for Wound Treatment and Soft Tissue Grafting** was revised to add bioengineered autologous skin-derived products (e.g., SkinTE) as investigational and not medically necessary.
- **MED.00126 – Fractional Exhaled Nitric Oxide and Exhaled Breath Condensate Measurements for Respiratory Disorders** was revised to add Nasal Nitric Oxide as investigational and not medically necessary in the diagnosis and monitoring of asthma and other respiratory disorders.
- **SURG.00037 – Treatment of Varicose Veins (Lower Extremities)** was revised:
 - To replace “nonsurgical management” with “conservative therapy” in the medically necessary criteria
 - To add sclerotherapy used in conjunction with a balloon catheter (e.g., catheter-assisted vein sclerotherapy [KAVS] procedure) as investigational and not medically necessary
- **TRANS.00035 – Mesenchymal Stem Cell Therapy for the Treatment of Joint and Ligament Disorders, Autoimmune, Inflammatory and Degenerative Diseases** (Previous title: Mesenchymal Stem Cell Therapy For Orthopedic Indications)
 - Includes the revised position statement: “Mesenchymal stem cell therapy is considered investigational and not medically necessary (INV&NMN) for the treatment of joint and ligament disorders caused by injury or degeneration as well as autoimmune, inflammatory and degenerative diseases”
- Expands the document’s scope to address non-FDA approved uses of mesenchymal stem cell therapy
- The following **AIM Specialty Health® updates** took effect on January 24, 2019:
 - Advanced Imaging
 - Imaging of the Heart
 - Imaging of the Head and Neck
 - Arterial Ultrasound
 - Joint Surgery
 - Sleep Disorder Management Diagnostic and Treatment

Medical Policies

On January 24, 2019, the Medical Policy and Technology Assessment Committee (MPTAC) approved several *Medical Policies* applicable to Summit Community Care.

Clinical UM Guidelines

On January 24, 2019, the MPTAC approved several *Clinical UM Guidelines* applicable to Summit Community Care. These guidelines were adopted by the medical operations committee for Summit Community Care members on March 28, 2019.

View the full update line for a list of the policies and guidelines recently developed and revised.



AR-NL-0033-19

Prior authorization requirements

Hyperbaric oxygen and supervision of hyperbaric oxygen therapy

Effective October 1, 2019, prior authorization (PA) requirements will change for hyperbaric oxygen and supervision of hyperbaric oxygen therapy to be covered by Summit Community Care.

PA requirements will be added to the following:

- Hyperbaric oxygen under pressure, full body chamber, per 30-minute interval (G0277)
- Physician attendance and supervision of hyperbaric oxygen therapy, per session (99183)

AR-NL-0037-19

Durable medical equipment

Effective December 1, 2019, prior authorization (PA) requirements will change for the codes listed below.

PA requirements will be added to the following:

- All lower extremity prosthesis – shank foot system with vertical loading pylon (L5987)
- Gait trainer, pediatric size – anterior support, includes all accessories and components (E8002)
- Wheelchair, pediatric size – tilt-in-space, folding, adjustable, without seating system (E1234)
- Wheelchair, pediatric size – tilt-in-space, rigid, adjustable, without seating system (E1233)
- Transport chair, pediatric size (E1037)
- Multi-positional patient transfer system with integrated seat, operated by care giver (E1035)
- Wheelchair accessory – ventilator tray, gimbaled (E1030)
- Water circulating heat pad with pump (E0217)

AR-NL-0039-19

Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. **Noncompliance with new requirements may result in denied claims.**

PA requirements will be added to the following:

- Web: <https://www.availity.com>
- Fax: 501-224-1355 (nonbehavioral health); 1-877-434-7578 (behavioral health)
- Phone: 1-844-462-0022

Not all PA requirements are listed here. PA requirements are available to contracted providers through the Availity Portal (<https://www.availity.com>). Providers who are unable to access Availity may call us at 1-844-462-0022 for PA requirements.

Reimbursement Policy

New Policy

Drug Screen Testing

(Policy 19-001, effective 10/01/19)

Summit Community Care allows separate reimbursement for definitive drug testing of 1-7 drug classes. Effective October 1, 2019, definitive drug testing for eight or more drug classes will not be separately reimbursed when performed on the same date of service as presumptive testing.

Definitive drug testing may be done to confirm the results of a negative presumptive test or to identify substances when there is no presumptive test available. Provider's documentation and member's medical records should reflect that the test was properly ordered and support that the order was based on the result of the presumptive test.

In the event a reference lab (POS = 81) performs both presumptive and definitive tests on the same date of service, records should reflect that the ordering/treating provider issued a subsequent order for definitive testing based on the results of the presumptive tests.

For additional information, refer to the Drug Screen Testing reimbursement policy at <https://www.summitcommunitycare.com/provider>.

AR-NL-0025-19